AzTrials
AzTrials

Oral Lichen PlanusEarly Phase 1OLPNCT03237533

Treatment Modalities of Oral Lichen Planus

A Early Phase 1 study testing Dexamethasone in people with Oral Lichen Planus, run by University of Faisalabad at 1 site in Pakistan.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Background: Oral lichen planus (OLP) is a chronic inflammatory mucocutaneous autoimmune disease mainly affecting stratum basal of the epithelium. It is very painful and hamper the daily routine of patients e.g. (talking, drinking, eating, maintaining normal relationships). Read more about this study

Who is it for?
Any age
Conditions the study is for
Oral Lichen Planus
What is being tested?
Dexamethasone
Could I receive a placebo?
No, everyone receives an active treatment
How many people
32 participants
Where
1 sitePakistan
Study dates
1 Jun 2017to 31 Dec 2017
Phase
Early Phase 1
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Any age
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Who may be able to join

  • 1. Histopathologically proven patients of OLP of all age groups complaining of symptoms such as pain, burning sensitivity to hot and spicy food.
  • 2. Who have signed informed consent.

Who cannot join

  • 1. Patients who have taken any medication for OLP within 4 weeks before the start of study.
  • 2. Pregnant and lactating women. 3. History of lichenoid reactions to beta blockers, dapsone, oral hypoglycemics, NSAIDS, pencillamine, phenothiazines, sulfonylureas, gold salts or amalgam fillings.

Trial locations and contacts

1 site in 1 country.

Sadaf Rashid, BDS contact

+923237791689

durr_e_sadaf@hotmail.com

Arsalan Wahid, M.Phil contact

+923216685228

dr.arsalanmalik@gmail.com

Pakistan1 site, 1 recruiting
  • The university of Faisalabad

    Faisalabad, Punjab Province, 38000

    Sadaf Rashid, BDS, +923237791689, durr_e_sadaf@hotmail.com

    Arsalan Wahid, M. Phil, +923216685228, dr.arsalanmalik@gmail.com

    Recruiting

Other trials in Pakistan

About this study

Official title: Comparative Efficacy of Dexamethasone, Doxycycline, Nystatin and Promethazine With Triamcinolone in Orabase as Symptomatic Treatment of Oral Lichen Planus, A Randomized Controlled Trial

Background: Oral lichen planus (OLP) is a chronic inflammatory mucocutaneous autoimmune disease mainly affecting stratum basal of the epithelium. It is very painful and hamper the daily routine of patients e.g. (talking, drinking, eating, maintaining normal relationships). Different topical treatments have been tried for the symptomatic relief of OLP which include topical corticosteroids (TCSs), topical calcineurin inhibitors (TCIs) retinoids, photochemotherapy; amitryptaline; thalidomide; amlexanox and traditional medicines such as curcumin, selenium-ACE combined with itraconazole, glycyrrhiza glabra and aloe vera. But the exact treatment is still unknown.

Objective: To compare the efficacy of Dexamethasone, Doxycycline, Nystatin and Promethazine cocktail with Triamcinolone as topical treatment of OLP Subjects and Methods: 40 patients of symptomatic OLP will be randomly divided in to study and control group. Study group will be given a cocktail containing dexamethasone, doxycycline, nystatin and promethazine and will be advised to rinse with 1 and half teaspoon of this cocktail 3 times a day for 2 minutes for the period of 8 weeks. Study group is also advised to apply an orabase containing 0.1% triamcinolone on lesions 3 times a day for the period of 8 weeks. The control group will be advised to apply only triamcinolone orabase 3 times a day for 8 weeks.

Read the detailed description

Introduction Oral lichen planus (OLP) is a chronic inflammatory mucocutaneous autoimmune disease mainly affecting stratum basal of the epithelium. It is T-cell mediated immunological disease that mostly occurs bilaterally on buccal mucosa while tongue and gingiva are other commonly involved sites while palatal mucosa and floor of the mouth are rarely affected (Roopashree MR, 2010, Torrente-Castells et al., 2010, Alves et al, 2010). The prevalence of OLP in general population is 0.1-4% (Sugerman et al., 2002) mainly affecting the middle-aged and elderly people (Ingafou et al., 2006) and female: male ratio 2:1 (Shen et al., 2012).

It has six clinical forms: keratotic, reticular, papular, plaquelike white patches, erosive, atrophic, and bullous (Shen et al., 2012). Reticular and erosive form are most common (Alves et al, 2010). Keratotic reticular, papular, plaque like white patches often present with no complaints (Oczko et al, 2011), while erosive, atrophic, and ulcerative lesions are a painful or present with a burning sensation, and thus make eating, speaking, and swallowing difficult (Thongprasom et al., 2007). Histologically, a subepithelial infiltration in the form of dense band of lymphocytes, increased numbers of intraepithelial lymphocytes and the liquefaction degeneration of basal keratinocytes is seen in OLP (Payeras et al., 2013).

Several predisposing factors have been identified which may cause or progress OLP which include immunity, infection, genetics, stress and endocrine. Recent researches showed an increased activity of prolidase and oxidative stress in OLP patients, causing disturbance in the antioxidant defense system (Batu et al, 2016, Ergun et al, 2011). Although the exact cause is still not clear, facts show that an immunological process is involved in OLP which is activated by an unknown antigen that change the basal keratinocytes of the oral mucosa and these alterations cause the cell immune response to attack the keratinocytes. (Ismail et al., 2007, Payeras et al., 2013). This antigen may be intrinsic or extrinsic, or both. Evidence shows that bacteria can be one of the etiologic factors of OLP. An association has already been found between OLP and infection, such as Ebstein Barr virus, Hepatitis C virus, Helicobacter pylori and Candida Albicans. A study also pointed out the allergy to various antigens coming in direct contact with oral cavity to contribute to the etiology of OLP. (D. Wray, 2000) As the etiology is not known therefore there is no definitive treatment for OLP and the mainstay of therapy for improving the life of these patients is symptomatic topical treatment. Topical treatments which have been tried for the symptomatic OLP include topical corticosteroids (TCSs), including betamethasone, clobetasol, dexamethasone and triamcinolone; topical calcineurin inhibitors (TCIs) such as pimecrolimus, tacrolimus or ciclosporin; retinoids such as tretinoin; photochemotherapy; amitryptaline; thalidomide; amlexanox and traditional medicines such as curcumin, selenium-ACE combined with itraconazole, glycyrrhiza glabra and aloe vera.

In a study both tacrolimus 0.1% ointment and pimecrolimus 1% cream were found equally effective for the treatment of OLP (Vohra et al., 2016). Similarly another study showed that Clobetasol propionate (0.05%) was found more effective than triamcinolone acetonate (0.1%) and tacrolimus orabase (0.03%) for the management of OLP. This study also found that triamcinolone 0.1% is superior to tacrolimus 0.03% in terms of effectiveness for the treatment of OLP.(Sivaraman et al., 2016) According to another study both triamcinolone and curcumin paste were found almost equally effective in reducing the pain and improving the appearance of OLP lesions (Kia et al., 2015). In another study it was concluded that combination of Selenium-ACE, corticosteroid and antifungal is a better treatment regimen for the treatment of erosive ulcerative OLP than a capsule of 100 mg Itraconazole plus dexamethsone mouthwash or dexamethasone alone (Belal, 2015). In another similar study cocktail of clobetasol, ketoconazole and amitryptiline was found more efficacious than diluted dexamethasone, nystatin and Diphenhydramine elixir (Javadzadeh et al, 2008). In a comparative study tacrolimus 0.1% cream was found more effective than 0.05% clobetasol propionate cream in reducing pain and healing of OLP lesions (Hettiarachchi et al., 2016). Both thalidomide and dexamethasone were found almost equally effective in another trail (Wu et al., 2010). In a trail of comperison between amlexanox paste and dexamethasone paste both were found equally effective at the end of 7 days in terms of reduction in clinical signs (erosion) and symptoms like pain and burning sensation (Fu et al., 2012). Some herbal medicines have also been tried like Glycyrrhiza glabra and Aloe vera, in a trail to compare the efficacy of 1% Glycyrrhiza glabra In orabase with 0.1% Triamcinolone Acetonide both were found almost equally effective in reducing the pain and improving the appearance of OLP lesions (Najafi et al., 2016) and in another trail both Aloe Vera Mouthwash and Triamcinolone Acetonide were found almost equally effective in reducing the pain and in reducing the size of OLP lesions (Mansourian et al., 2011) So steroids remained the mainstay of treatment for OLP but evidence points towards the involvement of bacterial and fungal infections in the pathogenesis of OLP as according to a recent study disbiosis was found in the buccal surface mucosa of patients of OLP, as certain bacterial species were found in greater no in buccal mucosa of OLP patients so they concluded that an association exists between bacterial disbiosis of buccal mucosa and OLP (He et al., 2017). Similar studies showed that antibiotics relieved symptoms of OLP effectively (Backman \& Jontell, 2007; Carbone et al, 1999). OLP is a disease which reduces the individual's resistance and changes the candida albican's role from commensalism to parasitism which is among the normal flora of oral cavity or candida may secondarily infect the OLP lesions and exacerbate the signs and symptoms (santosh gowdru shivanandappa, 2012). In a study 62% of OLP patients were found allergic to different allergens which come in contact with mucosa in daily life so they found that association exists between OLP and allergy (D. Wray, 2000). According to another study mast cell hyperplasia was seen in OLP patients which suggests their role in pathogenesis of OLP (Ankle R et al, 2007) The most used therapy is TCSs however its effectiveness is limited due to opportunistic oral infections in patients with OLP. Adjunct antibiotic therapies have been used to aid in symptomatic relief and improved response has been observed as compared to TCSs alone. however none of the combined therapies have used antifungal as an additive in their local applications, as candida is one of the opportunistic organisms that colonizes affected sites. Role of allergy mechanisms have also been discussed.

Rationale Evidence of involvement of bacterial and fungal infections and allergy in the pathogenesis of OLP suggests the need for the use of antibiotic, anti fungal and antihistamine for the topical treatment of OLP and there is a gap in literature. That's why current trail is being done to evaluate the efficacy of topical doxycycline, nyastatin and promethazine along with dexamethasone for the symptomatic relief of OLP.

Hypothesis Dexamethasone, Doxycycline, Nystatin and Promethazine combination topical rinse are more effective for the treatment of OLP than Triamcinolone alone Objective To compare the efficacy of Dexamethasone, Doxycycline, Nystatin and Promethazine combination topical rinse with Triamcinolone rinse as topical treatment of Oral Lichen Planus.

Operational Definitions • Oral Lichen Planus: Oral lichen planus (OLP) is a chronic inflammatory mucocutaneous autoimmune disease mainly affecting stratum basal of the epithelium.

Subjects and Methods Study Type Randomized control trail (Parallel arm study). Study Setting Department of Oral Medicine \& Diagnosis and Department of Dermatology. Madina Teaching Hospital Faisalabad.

Duration The study will be completed in 3 months after the approval of synopsis. Study Population Patients of oral lichen planus visiting Department of Oral Medicine \& Diagnosis and Department of Dermatology. Madina Teaching Hospital Faisalabad.

Sampling Technique Purposive Sampling, (Inclusion/exclusion criteria based)

Sample Selection Inclusion Criteria

  1. Histopathologically proven patients of OLP of all age groups complaining of symptoms such as pain, burning sensitivity to hot and spicy food.
  2. Who have signed informed consent. Exclusion Criteria

<!-- -->

  1. Patients who have taken any medication for OLP within 4 weeks before the start of study.
  2. Pregnant and lactating women.
  3. History of lichenoid reactions to beta blockers, dapsone, oral hypoglycemics, NSAIDS, pencillamine, phenothiazines, sulfonylureas, gold salts or amalgam fillings. Sample Size All consecutive OLP patients will be evaluated according to inclusion/exclusion criteria and at least 32 subjects will be enrolled they will be randomly divided into study and control groups. The sample size is calculated by the following formula keeping the power of study equal to 90% and level of significance equal to 0.05. The sample size should be 16 in each group. [p1(1 - p1) + p2 (1 - p2)] n = × cp,power (p1 - p2)2 (Whitley and Ball, 2002) Desired Level of Significance = 0.05 P1= proportion 1= 70% (0.7) P2= proportion 2= 30% (0.3) Cp, power = 90% =10.5 Sample size in each group = 16 Randomization Randomization will be done by allowing each patient to pick a sealed envelope from a box containing 40 envelopes of which 20 are of study and 20 are of control group. Study Variables Socio-demographic/Medical parameters • Age (years), • Gender (male / female), • Education (no-education / secondary / University), • Income (<10000.00- / 10-20000.00 / >20000.00),
  • Smoking (never / former / current),
  • Systemic conditions (CVD / DM / Hepatic / Rheumatoid Arthritis etc),
  • Medications
  • Oral hygiene habits (brushing, floss, dental visit) Oral parameters
  • Dimensions of lesion will be measured by with the help of a UNC-12 probe (HDL® Pakistan).
  • Color of lesion will be recorded by standardized pre and post treatment photographic record.
  • Pain or burning sensation will be evaluated by visual analogue scale (VAS).
  • Clinical response (improvement of lesions and symptoms) will be assessed by criteria given by (Escudier et al., 2007). Data Collection Method and Instruments After approval from the ethical review committee, patients will be included in the study. Written informed consent will be obtained from all patients prior to the study as a part of ethical practice. 40 patients of symptomatic OLP will be enrolled in the study after evaluation through punch biopsy and other inclusion and exclusion criteria to compensate the loss to follow up as the actual size calculated from the formula was 32. They will be randomly divided in to study and control group each containing 20 patients. At baseline visit after recording the socio-demographic and oral parameters data the local irritant factors in the oral cavity which can aggravate the OLP will be removed by doing basic oral procedures like scaling and root planning restorations, rounding of sharp cusps and replacement of any ill fitting appliances in both the groups. Study group will be given a cocktail containing dexamethasone, doxycycline, nystatin and promethazine and will be advised to rinse with 1 and half teaspoon of this cocktail 3 times a day for 2 minutes for the period of 8 weeks and do not eat or drink anything 30 minutes after its use. Study group will also advised to apply triamcinolone orabase containing 0.1% triamcinolone on lesions 3 times a day for the period of 8 weeks. The control group will be advised to apply only triamcinolone orabase 3 times a day for 8 weeks with the same protocol. Assessment of dimension of lesions, color, pain and burning sensation and improvement of lesions and symptoms will be done at baseline and after 4 and 8 weeks. Statistical Analysis The data will be coded and entered using SPSS ver 20. All the numerical variables will be presented as mean and standard deviation while the categorical variables will be reported as frequencies and percentages. the comparison of efficacy between two groups will be done through chi-square test. For all analysis a p-value of > 0.05 will be considered significant with a confidence level of 95% Ethical Considerations: Patients fulfilling the inclusion criteria will be informed about the aim of study, risks, benefits and a consent form will be signed by them. Study will be approved by Institutional Review Board (IRB), The University of Faisalabad.
Being tested
Dexamethasone
Medical subject headings
Lichen Planus, Oral

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • DexamethasoneDrug

    Also called Doxycycline, Nystatin, Promethazine, Triamcinolone Orabase

    Dexamethasone will be applied locally on the lesion

Study groups in NCT03237533
Study groupRoleWhat they receive
Study GroupActive comparatorin this group patients will be treated with Dexamethasone local application
Receives: Drug: Dexamethasone
Control GroupActive comparatorin this group patients will be treated with dexamethasone, doxycycline and nystattin
Receives: Drug: Dexamethasone

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. healing of lesions

    healing of oral lichen planus lesions

    Measured: 6 bmonths

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted2 Aug 2017
  2. Study start1 Jun 2017
  3. Primary completion1 Dec 2017 (estimated)
  4. Study completion31 Dec 2017 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
32 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03237533
Sponsor's protocol ID
123456789
Acronym
OLP
Status last verified
Jul 2017
First submitted
29 Jul 2017
Last updated
2 Aug 2017
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A Early Phase 1 study testing Dexamethasone in people with Oral Lichen Planus, run by University of Faisalabad at 1 site in Pakistan.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 2 Aug 2017. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Pakistan. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Early Phase 1 (sometimes called Phase 0) studies give a very small amount of a treatment to a few people, mainly to see how the body handles it.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Sadaf Rashid, BDS (+923237791689, durr_e_sadaf@hotmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

healing of lesions (time frame: 6 bmonths). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Aug 2017; AzTrials last refreshed its copy on 6 Nov 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in